openPR Logo
Press release

Hypomethylating Agents Market Study Reveals Growth Factors and Competitive Outlook for Future

01-21-2020 10:56 AM CET | Health & Medicine

Press release from: Kenneth Research

Hypomethylating Agents Market Study Reveals Growth Factors

Hypomethylating Agents Market: Introduction
Hypomethylating agents act as an essential tool in the treatment of health disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia. These are not the only available treatment options, but their use can further be integrated and optimized in a sequential treatment strategy. The hypomethylating agents are also called as DNA methyltransferase inhibitors. These have allowed the treatment of frail and higher-risk elderly patients.

Market Dynamics

Increasing MDS cases among the population within the age group of above 50 years is one of the major reasons driving the hypomethylating agents’ market significantly. According to the American Cancer Society, the number of people who are diagnosed with MDS in the U.S. every year is unknown, but according to a study conducted by this society, around 10,000 cases are being registered in the U.S. alone, while some other estimates are much higher.

Request To Download Sample of This Strategic Report: https://www.kennethresearch.com/sample-request-10220938

This health disorder is highly uncommon before the age of 50, and moreover, the health risks associated with disease gradually increases along with the person’s age. In the U.S., the new cases diagnosed each year are rising, as the average person’s age among the U.S. population is increasing. As the chances of disease outbreak are higher for this age group, the demand for hypomethylating agents is also predicted to grow over the forecast period.

Moreover, growing allogeneic stem cell transplants along with higher intensity approaches for the treatment of MDS, is expected to yield higher response rates and can also control the disease’s negative impact for longer times. These type of treatment facilities are increasing across the world, which will give an additional boost to the growth of hypomethylating agents market.

Hypomethylating agents market is expected to restrain, owing to the unmet need for sound treatment options among the patients. Moreover, the response rates of these agents for the control of disease’s impact is also very low, according to the National Institute of Health and American Cancer Society. These factors are expected to restrain the hypomethylating agents market significantly over the forecast period.

By Type of Treatment

By type of treatment, the hypomethylating agents market has been segmented into acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). Hypomethylating agents market for myelodysplastic syndromes is expected to have the dominant market share over the forecast period. Increasing new cases, coupled with the developing treatment options for this disorder are expected to attribute the prime share of hypomethylating agents market for myelodysplastic syndromes.

By Gender

Based on gender, the global hypomethylating agents market has been segmented into male and female. Over the forecast period, the use of hypomethylating agents for male population is projected to dominate the product use among female population.

This is majorly due to the higher disease incidence chances among men, compared to women. According to the estimates by the American Cancer Society, in 2017, around 19,520 new cases of AML have been identified in the U.S. alone, out of which more than 10,670 deaths are observed, which are mostly among adults, especially among men.

By Region

North America hypomethylating agents market is expected to have the prime share in the global market over the projected period. It is majorly attributed by the increasing cases, and growing treatment facilities, along with the presence of major research organizations (NIH, ACS), and pharmaceutical companies, which are currently striving towards the research and development of new drugs to treat MDS, and AML.

Asia Pacific hypomethylating agents market is expected to witness a higher growth over the forecast period, majorly owing to the presence of key pharmaceutical companies. Manufacturing companies in this region are majorly focusing on the development of these agents, owing to the increasing cases of MDS and AML.

Moreover, the governing bodies of several countries in this region are majorly focusing on the development of healthcare industry, which will provide lucrative opportunities for the hypomethylating agents market to grow over the forecast period.

Competitive Landscape

Some of the prominent players in the global hypomethylating agents market include Pfizer, Blue Point Laboratories, Actavis Pharma Company, Dr. Reddy’s Laboratories, Celgene, Cipla Limited, Otsuka Pharmaceuticals, Astex Pharmaceuticals, etc. among others.

Some key pharmaceutical companies such as Cipla Limited and Otsuka Pharmaceuticals are working constantly to get FDA approvals of the drugs developed. For instance, Cipla Limited received a final approval from the U.S. FDA for its generic drug Dacogen in November 2017.

Read More:- https://www.kennethresearch.com/report-details/hypomethylating-agents-market/10220938

Also, many prominent players are trying to obtain the rights from generic drug manufacturers to expand their geographic horizon in the global hypomethylating agents market. For instance, in March 2014, Otsuka Pharmaceuticals acquired rights from EISAI Inc. for the development and marketing of Dacogen in U.S., Canada, and Japan markets.

Contact Us:-
Name: David
Email : Sales@kennethresearch.com
Phone: +1 313 462 0609

About Kenneth Research:-
Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypomethylating Agents Market Study Reveals Growth Factors and Competitive Outlook for Future here

News-ID: 1902233 • Views: 149

More Releases from Kenneth Research

Photomask Market Growth Analysis by Revenue, Size, Share, Scenario on Latest Tre …
Kenneth Research provides an extensive study by our analysts which offers forecast assessment by correlating the historical data with key market dynamics. The Photomask Market further includes trends and opportunities that are highlighted, along with the market valuation. The market is segmented by segments and portrays the industry overview along with elaborate description of the market for the forecast period 2020-2025. The report also constitutes future growth statistics which is
Embedded Systems Market 2020 New Innovations Trends, Research, Global Share and …
Kenneth Research provides an extensive study by our analysts which offers forecast assessment by correlating the historical data with key market dynamics. The Embedded Systems Market further includes trends and opportunities that are highlighted, along with the market valuation. The market is segmented by segments and portrays the industry overview along with elaborate description of the market for the forecast period 2020-2025. The report also constitutes future growth statistics which
DNS Service Market : Industry Development Scenario and Forecast to 2025
Global DNS Service Market to reach USD 600 million by 2025.Global DNS Service Market valued approximately USD 230 million in 2016 is anticipated to grow with a healthy growth rate of more than 12% over the forecast period 2018-2025. The DNS Service Market is continuously growing across the world over the coming years. The major driving factor of global DNS Service market are increasing awareness to safeguard the websites from
Xenon Lights Market Growth, Size, Share, Demand, Trends and Manufacturers Analys …
Kenneth Research provides an extensive study by our analysts which offers forecast assessment by correlating the historical data with key market dynamics. The Xenon Lights Market further includes trends and opportunities that are highlighted, along with the market valuation. The market is segmented by segments and portrays the industry overview along with elaborate description of the market for the forecast period 2020-2025. The report also constitutes future growth statistics which

All 5 Releases


More Releases for Hypomethylating

Myelodysplastic Syndromes Market Business Growth Analysis, Trend, Outlook, Share …
Myelodysplastic Syndromes Market research report comprises of several parameters which are thoroughly studied by the experts. Market research analysis and data lend a hand to businesses for the planning of production, product launches, costing, inventory, purchasing and marketing strategies. This market study considers a market attractiveness analysis, where each segment is benchmarked based on its market size, growth rate, and general attractiveness. Market info can be explained more specifically in
Global Myelodysplastic Syndrome (MDS) Treatment Market Widespread Research and F …
Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around
Myelodysplastic Syndrome Treatment Market Size & Share - Industry Trends and For …
Marketresearchreports.biz has announced the addition of a new research study on the "Myelodysplastic Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025" to its report database. The main objective of this report is to define, describe, and forecast the global “Myelodysplastic Syndrome Treatment” market on the basis of types of applications, major sectors, deployment models, organization size, and regions. The report contains an
Myelodysplastic Syndrome Treatment Market Trends and Prospects by 2025
Myelodysplastic Syndrome Treatment Market: Overview Myelodysplastic syndrome (MDS) is a blood disorder caused due to the production of abnormal blood cells in bone marrow. Bone marrow failure leads to drop in the number of healthy blood cells in the body. In MDS, bone marrow does not produce healthy red blood cells, white blood cells, and/or platelets. Symptoms of MDS in the beginning are no specific than causes of pancytopenia i.e., deficiency
Global Myelodysplastic Syndrome (MDS) Treatment Drugs Market Is Expanding At CAG …
According to the latest market report published by Credence Research, Inc. “Myelodysplastic Syndrome (MDS) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025” the global myelodysplastic syndrome (MDS) treatment drugs market, expanding at a CAGR of 9.5% from 2017 to 2025. Browse the full report Myelodysplastic Syndrome (MDS) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017 – 2025 report at http://www.credenceresearch.com/report/myelodysplastic-syndrome-msds-treatment-drugs-market Market Insights Myelodysplastic syndrome (MDS)
Myelodysplastic Syndrome Treatment Market Expected to Expand at a Steady CAGR th …
Myelodysplastic syndrome (MDS) is a blood disorder caused due to the production of abnormal blood cells in bone marrow. Bone marrow failure leads to drop in the number of healthy blood cells in the body. In MDS, bone marrow does not produce healthy red blood cells, white blood cells, and/or platelets. Symptoms of MDS in the beginning are no specific than causes of pancytopenia i.e., deficiency of RBC, WBC and